Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Sponsor
NGM Biopharmaceuticals, Inc
Study ID
NCT07511972
Phase
PHASE2
Status
Withdrawn

Conditions

  • CRC

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NGM707 plus pembrolizumab — DRUG
    Drug: NGM707 NGM707 will be administered intravenously (IV) every 3 weeks in a 21 day cycle. Drug: pembrolizumab Pembrolizumab will be administered intravenously (IV) every 3 weeks in a 21 day cycle.

Study Details

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Key Dates

Start date
Nov 14, 2023
Status verified
Mar 2026
Primary completion
Dec 31, 2024
Completion
Sep 30, 2025

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: NGM707 Combination Cohort A
    NGM707 with pembrolizumab in MSS CRC

Primary Outcome Measure

Objective response rate (ORR) as per RECIST v1.1 [ Time Frame: Baseline up to approximately 24 months ]

Related Studies